What are the normal 25‑hydroxyvitamin D concentrations and recommended supplementation for deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Normal Vitamin D Levels and Supplementation

Normal 25-hydroxyvitamin D levels should be at least 30 ng/mL (75 nmol/L) for optimal health, with an upper safety limit of 100 ng/mL, and deficiency should be treated with 800-2000 IU daily for maintenance or 50,000 IU weekly for 8 weeks for correction. 1

Defining Normal Vitamin D Status

The international expert consensus establishes clear thresholds for vitamin D status 1:

  • Deficiency: <20 ng/mL (<50 nmol/L)
  • Insufficiency: 20-30 ng/mL (50-75 nmol/L)
  • Target optimal range: 30-40 ng/mL (75-100 nmol/L)
  • Upper safety limit: 100 ng/mL (250 nmol/L)

The target of at least 30 ng/mL is based on optimal health outcomes for both skeletal and non-skeletal benefits 1. While levels of 30-80 ng/mL are considered safe in clinical practice, supplementation is typically reduced when levels reach 70-80 ng/mL, as no additional benefits have been demonstrated above 50 ng/mL compared to 30-44 ng/mL 1.

Important Caveat on Recent Guidelines

The 2024 Endocrine Society guideline 2, 3 represents a significant shift, no longer endorsing specific 25(OH)D thresholds for "sufficiency" (≥30 ng/mL) or "insufficiency" (20-30 ng/mL) based on their analysis of recent large RCTs. However, this guideline focused specifically on disease prevention in generally healthy adults and found insufficient evidence to establish outcome-specific thresholds. For clinical practice managing patients with or at risk for musculoskeletal disease, cardiovascular disease, autoimmune conditions, and cancer, the 30 ng/mL threshold remains the established target 1.

Supplementation Recommendations

For High-Risk Groups (Without Baseline Testing)

The following groups can be supplemented empirically with 800 IU/day without measuring baseline levels 1:

  • Dark-skinned or veiled individuals with limited sun exposure
  • Adults ≥65 years old without specific health conditions
  • Institutionalized individuals

For Patients with Risk Factors (Measure First)

Measure 25(OH)D levels first, then supplement if <30 ng/mL in patients with 1:

  • Musculoskeletal health problems
  • Cardiovascular disease
  • Autoimmune disease
  • Cancer
  • Malabsorption syndromes

Treatment Algorithm for Deficiency

When 25(OH)D is <30 ng/mL 1:

  1. Correction phase: 50,000 IU vitamin D2 once weekly for 8 weeks
  2. Maintenance phase: 800 IU/day (or equivalent intermittent dosing)
  3. Monitor: Recheck 25(OH)D after at least 3 months
  4. Adjust: Increase dose if levels remain insufficient

Rule of thumb: 1,000 IU/day increases 25(OH)D by approximately 10 ng/mL, though individual responses vary 1.

Special Populations Requiring Higher Doses

Obese patients and those on certain medications (anticonvulsants, glucocorticoids) require 2-3 times more vitamin D (6,000-10,000 IU/day) to achieve and maintain levels >30 ng/mL 4.

Formulation Preferences

Vitamin D3 (cholecalciferol) is preferred over D2 (ergocalciferol) when both are available 1, particularly for intermittent dosing regimens, as D3 maintains serum levels longer. Both forms have similar effects when given as daily doses.

Critical Safety Considerations

Avoid single annual high-dose regimens (e.g., 500,000 IU annually), as RCTs have shown adverse outcomes with this approach 1. Daily, weekly, or monthly strategies are preferred.

Toxicity is rare: Hypercalcemia occurs only with daily intake >100,000 IU or 25(OH)D levels >100 ng/mL 1. Doses up to 10,000 IU/day for several months have not caused adverse events in studies 1.

Monitoring Requirements

  • Baseline measurement: Use assays measuring both 25(OH)D2 and 25(OH)D3 1
  • Follow-up timing: Wait at least 3 months after starting supplementation before rechecking levels 1
  • For intermittent dosing: Measure just before the next scheduled dose 1

Special Monitoring Situations

Patients with granulomatous diseases (sarcoidosis, tuberculosis) or lymphoma require careful monitoring of both 25(OH)D and calcium levels, as they produce 1,25(OH)2D unregulated, risking hypercalcemia when 25(OH)D exceeds 30 ng/mL 4.

Primary hyperparathyroidism patients can be treated for vitamin D deficiency but require serum calcium monitoring 4.

References

2
Guideline

vitamin d for the prevention of disease: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2024

3
Research

Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication.

The Journal of clinical endocrinology and metabolism, 2024

Related Questions

What loading and maintenance doses of liposomal vitamin D3 (cholecalciferol) and vitamin K2 should be used for a patient with a 25‑hydroxyvitamin D level of 28 ng/mL who is currently taking 1,000 IU vitamin D3 and 90 µg vitamin K daily?
How should an adult with documented vitamin D deficiency (25‑OH vitamin D <20 ng/mL) be treated?
For a patient with severe vitamin D deficiency (serum 25‑hydroxyvitamin D ≈ 11 ng/mL), how long should the treatment course last?
How severe is a serum vitamin D level of 150 ng/mL?
How should a patient with a 25‑hydroxy vitamin D level of 20 ng/mL be managed?
What does a thickened endometrium indicate?
What is the brand name and generic name of a combined intranasal antihistamine and corticosteroid spray?
What are the current standard first‑line systemic therapy options for an adult patient with stage IV colon cancer, including recommendations based on microsatellite instability‑high (MSI‑H) or mismatch‑repair deficient (dMMR) status versus microsatellite stable (MSS) disease?
Does vitamin C increase the risk of calcium oxalate kidney stones?
Is long‑term clopidogrel (75 mg daily) appropriate for secondary prevention after an ischemic stroke?
What are the appropriate medication doses for treating severe hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.